zalsupindole

Zalsupindole (DLX-001) is a novel non-hallucinogenic isotryptamine neuroplastogen developed for the treatment of major depressive disorder and other central nervous system disorders. It acts primarily as a selective serotonin 5-HT2 receptor modulator—specifically as an agonist at the 5-HT2A receptor and an antagonist at the 5-HT2B receptor. Preclinical studies have shown that it increases dendritic spine density in prefrontal cortex neurons and produces rapid and enduring antidepressant-like effects after a single dose. In phase 1 clinical trials in healthy volunteers and patients with major depressive disorder, DLX-001 demonstrated favorable safety and tolerability profiles without psychotomimetic or hallucinatory effects. The drug was discovered by Professor David E. Olson’s lab at the University of California, Davis and is being developed by Delix Therapeutics[1][2][3][4][8].

Other names

(R)-5-methoxy-N,N-dimethyl-α-methylisotryptamine(R)-5-MeO-α-methyl-isoDMT(R)-5-MeO-N,N-dimethyl-isoAMT